Previous 10 | Next 10 |
Merus (NASDAQ:MRUS) presents clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients with HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The primary endpoint of clinical benefit rate (CBR) at 24 ...
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the potential of zenocutuzumab in additional indication...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...
Merus (NASDAQ:MRUS) has priced its offering of 3.86M shares of common stock at $28.50/share, for expected gross proceeds of ~$110.0M. Underwriters' over-allotment is an additional 578,947 shares. All of the shares in the offering are to be sold by Merus. Net proceeds ...
Merus (NASDAQ:MRUS) launched a underwritten public offering of shares; underwriters granted 30-day option to purchase an additional 15% of the shares. Offer size, terms have not yet been disclosed. Net proceeds to be used for advancing the clinical development of its product candida...
Shares of Merus N.V. (NASDAQ:MRUS) traded at a new 52-week high today of $32.90. This new high was reached on above average trading volume as 1.2 million shares traded hands, while the average 30-day volume is approximately 847,000 shares. Merus NV is a clinical-stage immuno-oncology com...
Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indication Merus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual In...
Shares of Merus N.V. (NASDAQ:MRUS) traded today at $31.66, eclipsing its 52-week high. So far today approximately 1.2 million shares have been exchanged, as compared to an average 30-day volume of 737,000 shares. In the past 52 weeks, Merus N.V. share prices are bracketed by a low of $11...
While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...